These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38219557)

  • 1. Synthetic studies on the extracellular domain of the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) using Trt-K
    Iwamoto N; Sasaki J; Ohno S; Aoki K; Usui Y; Inuki S; Ohno H; Oishi S
    Bioorg Med Chem; 2024 Feb; 99():117585. PubMed ID: 38219557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT).
    Bolm L; Petruch N; Sivakumar S; Annels NE; Frampton AE
    J Clin Pathol; 2022 Apr; 75(4):217-221. PubMed ID: 35058314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry.
    Saito M; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Jun; 41(3):157-162. PubMed ID: 35736625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT.
    Matsuo T; Iguchi-Manaka A; Shibuya A; Shibuya K
    Cancer Sci; 2022 Nov; 113(11):4001-4004. PubMed ID: 35947095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain on CD4
    Kurita M; Yoshihara Y; Ishiuji Y; Chihara M; Ishiji T; Asahina A; Yanaba K
    J Dermatol; 2019 Jan; 46(1):37-42. PubMed ID: 30402886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
    Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
    J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain as a promising immune checkpoint target for the treatment of SLE.
    Zhao J; Li L; Feng X; Fan X; Yin H; Lu Q
    Lupus; 2024 Mar; 33(3):209-216. PubMed ID: 38291414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and characterization of polyclonal antibodies against mouse T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory domain by DNA-based immunization.
    Gao Y; Cui J; He W; Yue J; Yu D; Cai L; Xu H; Yang C; Chen ZK; Zhou H
    Transplant Proc; 2014; 46(1):260-5. PubMed ID: 24507063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
    Zhang P; Liu X; Gu Z; Jiang Z; Zhao S; Song Y; Yu J
    Biomark Res; 2024 Jan; 12(1):7. PubMed ID: 38229100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
    Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
    BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy].
    Wu J; Ren D; Bi H; Yi B; Wang H
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):819-827. PubMed ID: 36419396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
    Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H
    Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer.
    Sun J; Tian Y; Yang C
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Aug; ():. PubMed ID: 39158733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4
    Kamrani A; Soltani-Zangbar MS; Shiri S; Yousefzadeh Y; Pourakbari R; Aghebati-Maleki L; Mehdizadeh A; Danaii S; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Motavalli R; Zolfaghari M; Haji-Fatahaliha M; Mahmoodpoor A; Ahmadian Heris J; Emdadi A; Yousefi M
    Immunol Invest; 2022 May; 51(4):1023-1038. PubMed ID: 33855917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis.
    Ozmadenci D; Shankara Narayanan JS; Andrew J; Ojalill M; Barrie AM; Jiang S; Iyer S; Chen XL; Rose M; Estrada V; Molinolo A; Bertotto T; Mikulski Z; McHale MC; White RR; Connolly DC; Pachter JA; Kuchroo VK; Stupack DG; Schlaepfer DD
    Proc Natl Acad Sci U S A; 2022 Apr; 119(17):e2117065119. PubMed ID: 35467979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.
    Zhao J; Li L; Yin H; Feng X; Lu Q
    Int Immunopharmacol; 2023 Jul; 120():110358. PubMed ID: 37262959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell Immunoglobulin and ITIM Domain Contributes to CD8
    Song Y; Wang B; Song R; Hao Y; Wang D; Li Y; Jiang Y; Xu L; Ma Y; Zheng H; Kong Y; Zeng H
    Aging Cell; 2018 Apr; 17(2):. PubMed ID: 29349889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
    Shibuya A; Shibuya K
    Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.